New antibody combo shows promise in early cancer trial
NCT ID NCT06391775
First seen Oct 31, 2025 · Last updated May 08, 2026 · Updated 26 times
Summary
This trial tested a new antibody drug, GEN1055, in adults with advanced solid tumors. It was given alone or with pembrolizumab (with or without chemotherapy) to see if it is safe and works against cancer. The study was stopped early, but the goal was to find the best dose and measure how well it controls tumor growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinica Universidad de Navarra
Pamplona, 31008, Spain
-
Hospital Universtari Val D´Hebron
Barcelona, Spain
-
Start Madrid Ciocc Hm Sanchinarro
Madrid, Spain
-
Yale-New Haven Hospital
New Haven, Connecticut, 06510, United States
Conditions
Explore the condition pages connected to this study.